FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056532239> ?p ?o ?g. }

• W2056532239 abstract "Regulatory actions through 2007-2008 demonstrate FDA's response to multiple reports of sudden death and severe cardiopulmonary reactions temporally related to the administration of Ultrasound Contrast Agents (UCA). Certain animal data showed similar adverse effects at a clinically relevant dose. The products labels were changed to include the boxed warning encouraging healthcare providers to assess patients for contraindications and to monitor patients with pulmonary hypertension or unstable cardiac conditions. To further characterize risks, the manufacturers agreed to perform postmarketing studies in the outpatient setting, a retrospective study in the critically ill and a pulmonary hemodynamic study. Over 2008 FDA held two Advisory Committees to discuss UCA. The first in June, 2008, dealt with the issues of safety particularly relating to the rare cardiovascular reactions which had lead to the boxed warnings and the interpretation of pre-clinical data from various species. The Advisory Committee discussed the difficulty of characterizing safety in a study of a single arm design (all patients receiving the test UCA), particularly in patients with serious co-morbidities. The Advisory Committee emphasized the need for premarket prospective randomized studies in high risk populations who are likely to receive the product and also for large sample size post-marketing observational studies. Additionally the Advisory Committee re-confirmed the importance of pre-clinical data when obtained from a relevant species. The second Advisory Committee held in December, 2008 evaluated the possible approval of AI-700, a new UCA, with the proposed indication being the detection of coronary artery disease based on the assessment of myocardial perfusion and wall motion. The targeted population was patients with stable chest pain being evaluated for inducible ischemia. The Advisory Committee's finding of an unacceptable risk:benefit profile was based on the safety data as well as variations in diagnostic performance in the registration studies and failure to demonstrate the added value of AI-700 to non-contrast echocardiography. The major safety concerns related to the occurrence of hypotension following administration of the product. The process for UCA development from conception, pre-clinical studies, and early safety trials through registration trials leading to licensure should be evident to all stakeholders. The FDA website contains relevant recommendations from our Guidances and recent Advisory Committee meetings: Pre-market patients should be typical of the patients likely to receive the UCA in practice; a clinical benefit should be apparent; diagnostic efficacy should be self evident or derived from a sensitivity and specificity analysis compared to an existing standard, and safety where possible should be demonstrated through clinical trials. Through the new FDAAA legislation, FDA can now require post marketing studies for newly identified safety signals." @default.
• W2056532239 created "2016-06-24" @default.
• W2056532239 creator A5051920880 @default.
• W2056532239 date "2009-06-01" @default.
• W2056532239 modified "2023-09-26" @default.
• W2056532239 title "FDA perspective on ultrasound contrast agents safety and development" @default.
• W2056532239 doi "https://doi.org/10.1109/isbi.2009.5193158" @default.
• W2056532239 hasPublicationYear "2009" @default.
• W2056532239 type Work @default.
• W2056532239 sameAs 2056532239 @default.
• W2056532239 citedByCount "0" @default.
• W2056532239 crossrefType "proceedings-article" @default.
• W2056532239 hasAuthorship W2056532239A5051920880 @default.
• W2056532239 hasConcept C126322002 @default.
• W2056532239 hasConcept C17744445 @default.
• W2056532239 hasConcept C177713679 @default.
• W2056532239 hasConcept C194828623 @default.
• W2056532239 hasConcept C197934379 @default.
• W2056532239 hasConcept C23131810 @default.
• W2056532239 hasConcept C3017489713 @default.
• W2056532239 hasConcept C3116431 @default.
• W2056532239 hasConcept C535046627 @default.
• W2056532239 hasConcept C545542383 @default.
• W2056532239 hasConcept C71924100 @default.
• W2056532239 hasConceptScore W2056532239C126322002 @default.
• W2056532239 hasConceptScore W2056532239C17744445 @default.
• W2056532239 hasConceptScore W2056532239C177713679 @default.
• W2056532239 hasConceptScore W2056532239C194828623 @default.
• W2056532239 hasConceptScore W2056532239C197934379 @default.
• W2056532239 hasConceptScore W2056532239C23131810 @default.
• W2056532239 hasConceptScore W2056532239C3017489713 @default.
• W2056532239 hasConceptScore W2056532239C3116431 @default.
• W2056532239 hasConceptScore W2056532239C535046627 @default.
• W2056532239 hasConceptScore W2056532239C545542383 @default.
• W2056532239 hasConceptScore W2056532239C71924100 @default.
• W2056532239 hasLocation W20565322391 @default.
• W2056532239 hasOpenAccess W2056532239 @default.
• W2056532239 hasPrimaryLocation W20565322391 @default.
• W2056532239 hasRelatedWork W2035232177 @default.
• W2056532239 hasRelatedWork W2046347551 @default.
• W2056532239 hasRelatedWork W2085542262 @default.
• W2056532239 hasRelatedWork W2313076522 @default.
• W2056532239 hasRelatedWork W2765980456 @default.
• W2056532239 hasRelatedWork W2969890384 @default.
• W2056532239 hasRelatedWork W2976382042 @default.
• W2056532239 hasRelatedWork W2981703979 @default.
• W2056532239 hasRelatedWork W4281850960 @default.
• W2056532239 hasRelatedWork W2464797648 @default.
• W2056532239 isParatext "false" @default.
• W2056532239 isRetracted "false" @default.
• W2056532239 magId "2056532239" @default.
• W2056532239 workType "article" @default.